Pneumocystis jirovecii pneumonia: Still a concern in patients with haematological malignancies and stem cell transplant recipients

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages

  Cordonnier, Catherine ^a   Cesaro, Simone ^b   Maschmeyer, Georg ^c   Einsele, Hermann ^d   Donnelly, Peter ^e,m   Alanio, Alexandre ^f,g   Hauser, Philippe ^m   Lagrou, Katrien ^i,j   Melchers, Willem J G ^e   Helweg Larsen, Jannik ^k   Matos, Olga ^l   Bretagne, Stephane ^f   Maertens, Johan ^j   Agrawal, Samir ^m   Kibbler, Christopher ^m   Pagliuca, Antonio ^m   Ward, Katherine ^m   Akova, Murat ^m   Herbrecht, Raoul ^m   Mallet, Vincent ^m   Ribaud, Patricia ^m   Aljurf, Mahmoud ^m   Averbuch, Dina ^m   Engelhard, Dan ^m   Berg, Thomas ^m   Cornely, Oliver ^m   Penack, Olaf ^m   van Boemmel, Florian ^m   von Lilienfeld Toal, Marie ^m   Blennow, Ola ^m   Ljungman, Per ^m   Bruggemann, Roger ^m   Kullberg, Bart Jan ^m   Melchers, Willem ^m   Calandra, Thierry ^m   Hirsch, Hans ^m   Marchetti, Oscar ^m   Orasch, Christina ^m   Tissot, Frederic ^m   Castagnola, Elio ^m   Girmenia, Corrado ^m   Mikulska, Malgorzata ^m   Pagano, Livio ^m   Viscoli, Claudio ^m   De La Camara, Rafael ^m   Duarte, Rafael ^m   Munoz, Patricia ^m   Drgona, Lubos ^m   Hargreaves, Ruth ⁿ   Hubacek, Petr ^m   Kouba, Michal ^m   Racil, Zdenek ^m   Klyasova, Galina ^m   Pettrikos, George ^m   Roilides, Emmanuel ^m   Skiada, Anna ^m   Rizzi Puechal, Valérie ^o   Sinko, Janos ^m   Slavin, Monica ^m   Styczynski, Jan ^m   Tweddle, Lorraine ^p   Wood, Craig ^q   more..

^a HENRI MONDOR HOSPITAL   (France)

^b Policlinico Universitario gB Rossi   (Italy)

^c KLINIKUM ERNST VON BERGMANN   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HÔPITAL LARIBOISIÈRE   (France)

^g INSTITUT PASTEUR   (France)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k Rigshospitalet   (Denmark)

^l INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^m Universidade Nova de Lisboa ^*  (Poland)

ⁿ Gilead Sciences   (United Kingdom)

^o PFIZER INC   (United States)

^p Astellas   (United Kingdom)

^q LBNL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MONOCLONAL ANTIBODY; ANTIFUNGAL AGENT;

CANCER PATIENT; CLINICAL FEATURE; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; MORTALITY RATE; NONHUMAN; OUTCOME ASSESSMENT; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; ADVERSE EFFECTS; CHEMOPROPHYLAXIS; COMPLICATION; HEMATOLOGIC NEOPLASMS; ISOLATION AND PURIFICATION; MORTALITY; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PROCEDURES;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; STEM CELL TRANSPLANTATION; TRANSPLANT RECIPIENTS;

EID: 85015293304     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw155     Document Type: Review

References (92)

1. Hughes W, Price R, Kim H et al. Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr 1973; 82: 404-15.
2. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350: 2487-98.
3. Edman JC, Kovacs JA, Masur H et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 334: 519-22.
4. Alanio A, Hauser PM, Lagrou K et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; doi:10.1093/jac/dkw156
5. Maertens J, Cesaro S, Maschmeyer G et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; doi:10.1093/jac/dkw157
6. Maschmeyer G, Helweg-Larsen J, Pagano L et al. ECIL guidelines for the treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 2016; doi:10.1093/jac/ dkw158
7. HughesW, Feldman SA, Aur RJ. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975; 36: 2004-9.
8. Siegel S, Nesbit M, Baehner R et al. Pneumonia during therapy for childhood acute lymphoblastic leukemia. Am J Dis Child 1980; 134: 28-34.
9. Meyers J, Flournoy N, Thomas E. Nonbacterial pneumonia after allogeneic bone marrow transplantation. Rev Infect Dis 1982; 4: 1119-32.
10. Caselli D, Petris MG, Rondelli R et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr 2014; 164: 389-92 e1.
11. Matsumura Y, Ito Y, Yamamoto M et al. Pneumocystis polymerase chain reaction and blood (1-3)-b-D-glucan assays to predict survival with suspected Pneumocystis jirovecii pneumonia. J Infect Chemother 2013; 20: 109-14.
12. McKinnell JA, Cannella AP, Kunz DF et al. Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Transpl Infect Dis 2012; 14: 510-8.
13. Pagano L, Fianchi L, Mele L et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117: 379-86.
14. Zahar J, Robin M, Azoulay E et al. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis 2002; 35: 929-34.
15. Maini R, Henderson KL, Sheridan EA et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis 2013; 19: 386-92.
16. Roblot F, Imbert S, Godet C et al. Risk factors analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia. Scand J Infect Dis 2004; 36: 848-54.
17. Roblot F, Le Moal G, Kauffmann-Lacroix C et al. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. Scand J Infect Dis 2014; 46: 210-4.
18. Sillaber C, Herrmann H, Bennett K et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009; 39: 1098-109.
19. Frickhofen N, Kaltwasser JP, Schrezenmeier H et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med 1991; 324: 1297-304.
20. Marsh JC, Bacigalupo A, Schrezenmeier H et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 2012; 119: 5391-6.
21. Scheinberg P, Nunez O,Weinstein B et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430-8.
22. Toma A, Fenaux P, Dreyfus F et al. Infections in myelodysplastic syndromes. Haematologica 2012; 97: 1459-70.
23. Barbounis V, Aperis G, Gambletsas E et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res 2005; 25: 651-5.
24. Huang YC, Liu CJ, Liu CYet al. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 2011; 90: 1145-51.
25. Kovacs J, Hiemenz J, Macher A et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Medicine 1984; 100: 663-71.
26. Torres HA, Chemaly RF, Storey R et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006; 25: 382-8.
27. Mansharamani N, Garland R, Delaney D et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995. Comparison of HIV-associated cases to other immunocompromised states. Chest 2000; 118: 704-11.
28. Toper C, Rivaud E, Daniel C et al. Pneumocystose pulmonaire chez des patients immunodéprimés non infectés par le VIH: étude de 41 cas. Rev Pneumol Clin 2011; 67: 191-8.
29. Ricks DM, Chen K, Zheng M et al. Dectin immunoadhesins and Pneumocystis pneumonia. Infect Immun 2013; 81: 3451-62.
30. Schoffelen AF, van Lelyveld SF, Barth RE et al. Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands host or environmental factors? AIDS 2013; 27: 1179-84.
31. Martin-Garrido I, Carmona E, Specks U et al. Pneumocystis pneumonia in patients treated with rituximab. Chest 2013; 144: 258-65.
32. Sepkowitz K. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993; 17: S416-22.
33. Sepkowitz K, Brown A, Telzac E et al. Pneumocystis carinii pneumonia among patientswithout AIDS at a cancer hospital. JAMA 1992; 267: 832-7.
34. Yale S, Limper A. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc 1996; 71: 5-13.
35. Limper A, Offord K, Smith T et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140: 1204-9.
36. Kulke MH, Vance EA. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis 1997; 25: 215-8.
37. Kane GC, Israel HL, Peters SP. Pneumocystis carinii pneumonia and methotrexate therapy. Chest 1993; 103: 1923.
38. Kuitert LM, Harrison AC. Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma. Thorax 1991; 46: 936-7.
39. O'Brien S, Kantarjian H, Beran M et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-700.
40. Byrd JC, Hargis JB, Kester KE et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995; 49: 135-42.
41. Tsimberidou AM, Younes A, Romaguera J et al. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 2005; 104: 345-53.
42. Obeid KM, Aguilar J, Szpunar S et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk 2012; 12: 66-9.
43. Kim SY, Dabb AA, Glenn DJ et al. Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatr Blood Cancer 2008; 50: 779-83.
44. Kolstad A, Holte H, Fossa A et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007; 92: 139-40.
45. Kamel S, O'Connor S, Lee N et al. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51: 797-801.
46. Haeusler GM, Slavin MA, Seymour JF et al. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. Eur J Haematol 2013; 91: 157-63.
47. Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-7.
48. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-23.
49. Karlsson C, Norin S, Kimby E et al. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 2006; 20: 2204-7.
50. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-61.
51. Lin TS, Donohue KA, Byrd JC et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010; 28: 4500-6.
52. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-73.
53. Martin SI, Marty FM, Fiumara K et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43: 16-24.
54. Wendtner CM, Ritgen M, Schweighofer CD et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093-101.
55. Kim SJ, Moon JH, Kim H et al. Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. Leuk Lymphoma 2012; 53: 1515-24.
56. Meyers JD, Pifer LL, Sale GE et al. The value of Pneumocystis carinii antibody and antigen detection for diagnosis of Pneumocystis carinii pneumonia after marrow transplantation. Am Rev Respir Dis 1979; 120: 1283-7.
57. Chen CS, Boeckh M, Seidel K et al. Incidence, risk factors, and mortality frompneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 515-22.
58. De Castro N, Neuvielle S, Sarfati C et al. Occurrence of Pneumocystis jirovecii after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005; 36: 879-83.
59. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992; 10: 267-72.
60. Vasconcelles MJ, Bernardo MV, King C et al. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 2000; 6: 35-43.
61. Colby C, McAfee S, Sackstein R et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 897-902.
62. Tomonari A, Takahashi S, Ooi J et al. No occurrence of Pneumocystis jiroveci (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation. Transpl Infect Dis 2008; 10: 303-7.
63. Souza JP, Boeckh M, Gooley TA et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999; 29: 1467-71.
64. Bjorklund A, Aschan J, Labopin M et al. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 40: 1055-62.
65. Sepkowitz K.Opportunistic infections in patients with and patientswithout acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34: 1098-107.
66. Pyrgos V, Shoham S, Roilides E et al. Pneumocystis pneumonia in children. Paediatr Respir Rev 2009; 10: 192-8.
67. Saltzman RW, Albin S, Russo P et al. Clinical conditions associated with PCP in children. Pediatr Pulmonol 2012; 47: 510-6.
68. Lindemulder S, Albano E. Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii ( jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007; 120: e47-51.
69. Ng V, Yajko D, Hadley W. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997; 10: 401-18.
70. Ainoda Y, Hirai Y, Fujita T et al. Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia. J Infect Chemother 2012; 18: 722-8.
71. Monnet X, Vidal-Petiot E, Osman D et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Critical Care 2008; 12: 1-9.
72. Vogel M, Brodoefel H, Hierl T et al. Differences and similarities of cytomegalovirus and pneumocystis pneumonia in HIV-negative immunocompromised patients-thin section CT morphology in the early phase of the disease. Br J Radiol 2007; 80: 516-23.
73. Henson J, Jalaj J, Walker R et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991; 84: 406-9.
74. HuhW, Gill J, Sheth S et al. Pneumocystis carinii pneumonia in patients with Diamond-Blackfan anemia receiving high-dose corticosteroids. J Pediatr Hematol Oncol 2002; 24: 410-2.
75. van der Lelie J, Venema D, Kuijper E et al. Pneumocystis carinii pneumonia in HIV-negative patients with haematologic disease. Infection 1997; 25: 78-81.
76. Poulsen A, Demeny AK, Bang Plum C et al. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 2001; 37: 20-3.
77. Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIVinfected patients in the era of novel immunosuppressive therapies. J Infect Chemother 2012; 18: 793-806.
78. Hardak E, Brook O, Yigla M. Radiological features of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without AIDS. Lung 2010; 188: 159-63.
79. Vogel M, Weissberger P, Goeppert B et al. Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jiroveci pneumonia. Swiss Med Wkly 2011; 141: w13184.
80. Ewig S, Bauer T, Schneider C et al. Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressed patients. Eur Respir J 1995; 8: 1548-53.
81. Fillatre P, Chevrier S, Revest M et al. Human herpes virus co-infection is associated with mortality in HIV-negative patients with Pneumocystis jirovecii pneumonia. Eur J Clin Microbiol Infect Dis 2013; 32: 189-94.
82. Nakazato T, Mihara A, Sanada Y et al. Pneumocystis jiroveci pneumonia detected by FDG-PET. Ann Hematol 2010; 89: 839-40.
83. Bollee G, Sarfati C, Thiery G et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 2007; 132: 1305-10.
84. Boiselle P, Crans C, Kaplan M. The changing face of Pneumocystis carinii pneumonia in AIDS patients. Am J Roentgenol 1999; 172: 1301-9.
85. Chow C, Templeton P, White C. Lung cysts associated with Pneumocystis carinii pneumonia: radiographic characteristics, natural history, and complications. AJR 1993; 161: 527-31.
86. Tasaka S, Tokuda H, Sakai F et al. Comparison of clinical and radiological features of Pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med 2010; 49: 273-81.
87. Marchiori E, Zanetti G, Hochhegger B et al. Reversed halo sign on computed tomography: state-of-the-art review. Lung 2012; 190: 389-94.
88. Otara H, Tada K, Sakurai T et al. Reversed halo sign in pneumocystis pneumonia: a case report. BMC Med Imaging 2010; 10: 26.
89. Win Z, Todd J, Al-Nahhas A. FDG-PET imaging in Pneumocystis carinii pneumonia. Clin Nucl Med 2005; 30: 690-1.
90. Elias S, Almogi-Hazan O, Aker M et al. A diagnostic challenge: PcP in a non-HIV patient. Q J Med 2011; 104: 889-91.
91. Moriyama K, Muranishi H, Nishimura J et al. Immunodeficiency in preclinical smoldering adult T-cell leukemia. Jpn J Clin Oncol 1988; 18: 363-9.
92. Hardak E, Oren I, Dann EJ et al. The increased risk for Pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience. Acta Haematol 2012; 127: 110-4.